Abstract
Eosinophilic esophagitis (EoE), a chronic relapsing antigen-driven disease, is associated with characteristic esophageal histopathology, including ≥15 intraepithelial eosinophils in at least one high-power field (HPF), and alterations in the epithelium and subepithelial connective tissue. Currently, the pathologic changes in EoE are characteristic but not pathognomonic: the differential diagnosis includes gastroesophageal reflux disease, proton pump inhibitor-responsive esophageal eosinophilia, EoE with significant eosinophilic inflammation in other parts of the gastrointestinal tract (eosinophilic gastrointestinal disorder), etc. EoE biopsy pathology does not vary according to age, sex, or familial predisposition. Genetic analyses of EoE esophageal biopsies have identified a characteristic transcriptome that includes upregulation of several genes that relate to histopathology, such as periostin, thymic stromal lymphopoietin, and desmoglein. Diagnostic pitfalls include the patchy distribution of the characteristic EoE pathology; examining multiple biopsies increases the disease detection rate. The method used to quantitate eosinophils, including the size of the HPF, influences the diagnostic yield, but excellent interobserver variability is achieved among pathologists who agree to a uniform methodology. Therapy for EoE includes diet-based approaches to eliminate offending antigens, topical steroid therapy, and novel biologic agents including monoclonal antibodies. Following appropriate therapy, biopsies may revert to normal histology, but signs and symptoms of esophageal dysfunction may persist. A potential explanation is that endoscopic biopsies obtain very small superficial fragments of tissue from an organ that has complex underlying neuromuscular components; unseen pathology in those loci may influence the clinical state of patients with normal epithelial biopsies.
References
1.
Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, Bonis P, Hassall E, Straumann A, Rothenberg ME, First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees: Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342-1363.
2.
Liacouras CA, Spergel JM, Ruchelli E, Verma R, Mascarenhas M, Semeao E, Flick J, Kelly J, Brown-Whitehorn T, Mamula P, Markowitz JE: Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005;3:1198-1206.
3.
Assa'ad AH, Putnam PE, Collins MH, Akers RM, Jameson SC, Kirby CL, Buckmeier BK, Bullock JZ, Collier AR, Konikoff MR, Noel RJ, Guajardo JR, Rothenberg ME: Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J Allergy Clin Immunol 2007;119:731-738.
4.
Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, Burks AW, Chehade M, Collins MH, Dellon ES, Dohil R, Falk GW, Gonsalves M, Gupta SK, Katzka DA, Lucendo AJ, Markowitz JE, Noel RJ, Odze RD, Putnam PI, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer A, Shaheen NJ, Sicherer SH, Spechler S, Spergel JM, Straumann A, Weshil BK, Rothenberg ME, Aceves SS: Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3-20.
5.
Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA: ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013;108:679-692.
6.
DeBrosse CW, Case JW, Putnam PE, Collins MH, Rothenberg ME: Quantity and distribution of eosinophils in the gastrointestinal tract of children. Pediatr Dev Pathol 2006;9:210-218.
7.
Walsh SV, Antonioli DA, Goldman H, Fox VL, Bousvaros A, Leichtner AM, Furuta GT: Allergic esophagitis in children. A clinicopathologic entity. Am J Surg Pathol 1999;23:390-396.
8.
Dellon ES, Fritchie KJ, Rubinas TC, Woosley JT, Shaheen NJ: Inter- and intraobserver reliability and validation of a new method for determination of eosinophil counts in patients with esophageal eosinophilia. Dig Dis Sci 2010;55:1940-1949.
9.
Gonsalves N, Policarpio-Nicolas M, Zhang Q, Sambasiva Rao M, Hirano I: Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006;64:313-319.
10.
Molina-Infante J, Ferrando-Lamana L, Ripoll C, Hernandez-Alonso M, Mateos JM, Fernandez-Bermejo M, Dueñas C, Fernandez-Gonzalez N, Quintana EM, Gonzalez-Nuñez MA: Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011;9:110-117.
11.
Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR: Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 2013;62:489-495.
12.
Lwin T, Melton SD, Genta RM: Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil count. Mod Pathol 2011;24:556-563.
13.
Straumann A, Aceves SS, Blanchard C, Collins MH, Furuta GT, Hirano I, Schoepfer AM, Simon D, Simon H-U: Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy 2012;67:477-490.
14.
Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, Jameson SC, Kirby C, Konikoff MR, Collins MH, Cohen MB, Akers R, Hogan SP, Assa'ad AH, Putnam PE, Aronow BJ, Rothenberg ME: Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006;116:536-547.
15.
Abonia JP, Blanchard C, Buckmeier Butz B, Rainey HF, Collins MH, Stringer K, Putnam PE, Rothenberg ME: Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 2010;126:140-149.
16.
Blatman KS, Gonsalves N, Hirano I, Bryce PJ: Expression of mast-cell associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy. J Allergy Clin Immunol 2011;127:1307-1308.
17.
Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU: Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003;125:1660-1669.
18.
Aceves SS, Newbury RO, Dohil R, Bastian JF, Broide DH: Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2007;119:206-212.
19.
Chehade M, Sampson HA, Morotti RA, Magid MS: Esophageal subepithelial fibrosis in children with eosinophilic esophagitis. J Pediatr Gastro Nutr 2007:45:319-328.
20.
Aceves SS, Newbury RO, Chen D, Mueller J, Dohil R, Hoffman H, Bastian JF, Broide DH: Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy 2010;65:109-116.
21.
Lucendo AJ, Árias A, De Rezende LC, Yagüe-Compadre JL, Mota-Huertas T, González-Castillo S, Cuesta RA, Tenias JM, Bellon T: Subepithelial collagen deposition, profibrogenic cytokine gene expression, and changes after prolonged fluticasone propionate treatment in adult eosinophilic esophagitis: a prospective study. J Allergy Clin Immunol 2011;128:1037-1046.
22.
Lieberman JA, Morotti RA, Konstantinou GN, Yershov O, Chehade M: Dietary therapy can reverse esophageal subepithelial fibrosis in patients with eosinophilic esophagitis: a historical cohort. Allergy 2012;67:1299-1307.
23.
Vanderheyden AD, Petras RE, DeYoung BR, Mitros FA: Emerging eosinophilic (allergic) esophagitis: increased incidence or increased recognition? Arch Pathol Lab Med 2007;131:777-779.
24.
Whitney-Miller CL, Katzka D, Furth EE: Eosinophilic esophagitis: a retrospective review of esophageal biopsy specimens from 1992 to 2004 at an adult academic medical center. Am J Clin Pathol 2009;131:788-792.
25.
Gill R, Durst P, Rewalt M, Elitsur Y: Eosinophilic esophagitis disease in children from West Virginia: a review of the last decade (1995-2004). Am J Gastroenterol 2007;102:2281-2285.
26.
Debrosse CW, Collins MH, Buckmeier Butz BK, Allen CL, King EC, Assa'ad AH, Abonia JP, Putnam PE, Rothenberg ME, Franciosi JP: Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982-1999. J Allergy Clin Immunol 2010;126:112-119.
27.
Debrosse CW, Franciosi JP, King EC, Buckmeier Butz BK, Greenberg AB, Collins MH, Abonia JP, Assa'ad A, Putnam PE, Rothenberg ME: Long-term outcomes in pediatric-onset esophageal eosinophilia. J Allergy Clin Immunol 2011;128:132-138.
28.
Collins MH, Blanchard C, Abonia JP, Kirby C, Akers R, Wang N, Putnam PE, Jameson SA, Assa'ad AH, Konikoff MR, Stringer KF, Rothenberg ME: Clinical, pathologic and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol 2008;6:621-629.
29.
Abonia JP, Wen T, Stucke EM, Grotjan T, Griffith MS, Kemme KA, Collins MH, Putnam PE, Franciosi JP, von Tiehl KF, Tinkle BT, Marsolo KA, Martin LJ, Ware SM, Rothenberg ME: High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol 2013;132:378-386.
30.
Ngo P, Furuta GT, Antonioli DA, Fox VL: Eosinophils in the esophagus - peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006;101:1666-1670.
31.
Rodrigo S, Abboud G, Oh D, DeMeester SR, Hagen J, Lipham J, DeMeester TR, Chandrasoma P: High intraepithelial eosinophil counts in esophageal squamous epithelium are not specific for eosinophilic esophagitis in adults. Am J Gastroenterol 2008;103:435-442.
32.
Dranove JE, Horn DS, Davis MA, Kernek KM, Gupta SK: Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 2009;154:96-100.
33.
Dohil R, Newbury RO, Aceves S: Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci 2012;57:1413-1419.
34.
Moawad FJ, Veerappan GR, Dias JA, Baker TP, Maydonovitch CL, Wong RK: Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2013;108:366-372.
35.
Schroeder S, Capocelli KE, Masterson JC, Harris R, Protheroe C, Lee JJ, Furuta GT: Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr 2013;56:166-172.
36.
Hirano I: Editorial: should patients with suspected eosinophilic esophagitis undergo a therapeutic trial of proton pump inhibition? Am J Gastroenterol 2013;108:373-375.
37.
Kirsch R, Bokhary R, Marcon MA, Cutz E: Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;44:20-26.
38.
Dellon ES, Chen X, Miller CR, Fritchie KJ, Rubinas TC, Woosley JT, Shaheen NJ: Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. Am J Gastroenterol 2011;106:264-271.
39.
Sridhara S, Ravi K, Smyrk TC, Kita H, Kephart GM, Weiler CR, Katzka DA: Increased numbers of eosinophils, rather than only etiology, predict histologic changes in patients with esophageal eosinophilia. Clin Gastroenterol Hepatol 2012;10:735-741.
40.
Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, Akers R, Cohen MB, Collins MH, Assa'ad AH, Aceves SS, Putnam PE, Rothenberg ME: A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:1381-1391.
41.
Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephardt GM, Kita H, Kryzer LA, Romero Y, Smyrk TAC, Talley NJ: Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012;10:742-749.
42.
Dohil R, Newbury R, Fox L, Bastian J, Aceves S: Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139:418-429.
43.
Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, Bussman C, Beglinger C, Schoepfer A, Simon HU: Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010;139:1526-1537.
44.
Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, Perschy TL, Jurgensen CH, Ortega HG, Aceves SS: An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011;141:1593-1604.
45.
Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G, O'Gorman MA, Abonia JP, Young J, Henkel T, Wilkins HJ, Liacouras CA: Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129:456-463.
46.
Rothenberg ME, Spergel JM, Sherrill JD, Annaiah K, Martin LJ, Cianferoni A, Gober L, Kim C, Glessner J, Frackelton E, Thomas K, Blanchard C, Liacouras C, Verma R, Aceves S, Collins MH, Brown-Whitehorn T, Putnam PE, Franciosi JP, Chiavacci RM, Grant SFA, Abonia JP, Sleiman PM, Hakonarson H: Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet 2010;42:289-291.
47.
Sherrill JD, Gao PS, Stucke EM, Blanchard C, Collins MH, Putnam PE, Franciosi JP, Kushner JP, Abonia JP, Assa'ad AH, Kovacic MB, Myers JM, Bochner BS, He H, Hershey GK, Martin LJ, Rothenberg ME: Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol 2010;126:160-165.
48.
Noti M, Wojno ED, Kim BS, Siracusa MC, Giacomin PR, Nair MG, Benitez AJ, Ruymann KR, Muir AB, Hill DA, Chikwava KR, Moghaddam AE, Sattentau QJ, Alex A, Zhou C, Yearley JH, Menard-Katcher P, Kubo M, Obata-Ninomiya K, Karasuyama H, Comeau MR, Brown-Whitehorn T, Malefyt RW, Sleiman PM, Hakonarson H, Cianferoni A, Falk GW, Wang M-L, Spergel JM, Artis D: Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat Med 2013;19:1005-1013.
49.
Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, Stringer K, Abonia JP, Molkentin JD, Rothenberg ME: Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 2008;1:289-296.
50.
Blanchard C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, Buckmeier BB, Jameson SC, Greenberg A, Kaul A, Franciosi JP, Kushner JP, Martin LJ, Putnam PE, Abonia JP, Wells SI, Rothenberg ME: Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol 2010;184:4033-4041.
51.
Lu TX, Sherrill JD, Wen T, Plassard AJ, Besse JA, Abonia JP, Franciosi JP, Putnam PE, Eby M, Martin LJ, Aronow BJ, Rothenberg ME: MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol 2012;129:1064-1075.
52.
Lu S, Mukkada VA, Mangray A, Cleveland K, Shillingford N, Schorl C, Brodsky AS, Resnick MB: MicroRNA profiling in mucosal biopsies of eosinophilic esophagitis patients pre and post treatment with steroids and relationship with mRNA targets. PLoS One 2012;7:e40676.
53.
Wen T, Stucke E, Grotjan TG, Kemme K, Abonia JP, Putnam PE, Franciosi JP, Garza JM, Kaul A, King EC, Collins MH, Kushner JP, Rothenberg ME: Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology 2013, e-pub ahead of print.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
